Vistagen Therapeutics, Inc.
VTGN · XNASCIK 1411685fmd_1BH2DNPBRQKFABBCT7C3HNJZ9DManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Apr 01, 1999 to Jun 30, 2026, 76 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 0 | – | 0 | 1 | 1 | (0) | 1 | 0 | 1 |
| Net interest income | – | – | (0) | 0 | 0 | 0 | 0 | – | – | – |
| Research and development | 5 | 8 | 17 | 13 | 12 | 35 | 44 | 20 | 39 | 55 |
| Total operating expenses | 11 | 14 | 25 | 21 | 19 | 49 | 59 | 34 | 56 | 73 |
| Operating income | (10) | (14) | (25) | (21) | (18) | (48) | (59) | (33) | (56) | (72) |
| Interest expense | 0 | 0 | 0 | – | – | – | – | – | – | – |
| Other non-operating income (expense) | 0 | – | – | – | 0 | 0 | – | – | – | – |
| Income before taxes | (10) | (14) | (25) | (21) | (18) | (48) | (59) | (29) | (51) | (70) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (10) | (14) | (25) | (21) | (18) | (48) | (59) | (29) | (51) | (70) |
| Net income | (10) | (14) | (25) | (21) | (18) | (48) | (59) | (29) | (51) | (70) |
| Net income to common shareholders | (12) | (16) | (26) | (22) | (42) | (49) | (59) | – | – | – |